Observations placeholder
Ebrantil
Identifier
018935
Type of Spiritual Experience
Background
A description of the experience
Urapidil is a sympatholytic antihypertensive drug. It acts as an α1-adrenoceptor antagonist and as an 5-HT1A receptor agonist. Although an initial report suggested that urapidil was also an α2-adrenoceptor agonist this was not substantiated in later studies that demonstrated it was devoid of agonist actions in the dog saphenous vein and the guinea-pig ileum. Unlike some other α1-adrenoceptor antagonists, urapidil is believed not to elicit reflex tachycardia, and this may be related to its weak β1-adrenoceptor antagonist activity as well as its effect on cardiac vagal drive. Urapidil is currently not approved by the U.S. Food and Drug Administration, but it is available in Europe. From the figures, however, it appears to be being prescribed.
On Dec, 1, 2015: 474 people reported to have side effects when taking Ebrantil. Among them, 8 people (1.69%) have Hallucination.
On Nov, 19, 2015: 474 people reported to have side effects when taking Ebrantil. Among them, 4 people (0.84%) have Death.
Time on Ebrantil when people have Death :
< 1 month1 - 6 months6 - 12 months1 - 2 years2 - 5 years5 - 10 years10+ years Death0.00%100.00%0.00%0.00%0.00%0.00%0.00%